CPC G16B 20/20 (2019.02) [A61K 38/1793 (2013.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C07K 16/241 (2013.01); G16B 40/00 (2019.02); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 50/20 (2018.01); G16H 50/70 (2018.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01)] | 14 Claims |
1. A method of treating a subject suffering from rheumatoid arthritis, the method comprising administering to the subject an alternative to anti-TNF therapy,
wherein the subject has been predicted to be non-responsive to the anti-TNF therapy based at least in part on a trained machine learning classifier that distinguishes between responsive subjects and non-responsive subjects who have received the anti-TNF therapy,
wherein the trained machine learning classifier distinguishes between the responsive subjects and the non-responsive subjects, based at least in part on analyzing an expression level in the subject of a set of genes.
|